KYTX Kyverna Therapeutics, Inc.
Nasdaq · SEC CIK 1994702 · EDGAR
- Bought, last 12 months
- $2.00M 2 purchases by 2 insiders
- Sold, last 12 months
- $292.8K 1 sales by 1 insiders
- Filings on record
- 41 since 2024-02-12, latest 2026-05-29 16:30
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Westlake BioPartners Opportunity Fund I, L.P. | 10% | $1000.0K | — |
| SEIDENBERG BETH C | Dir | $1000.0K | — |
| Walker Karen Marie | CTO | — | $292.8K |
| GEHCHAN NAJI | See Remarks | — | — |
| Aktar Mert | Dir | — | — |
| Biddle Warner Weston | CEO, Dir | — | — |
| Emany Sravan Kumar | Dir | — | — |
| Miller Andrew Craig | Dir | — | — |
| GRASSO MARC | CFO | — | — |
| Shaw Christi | Executive COB, Dir | — | — |
Transactions 36
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-29 16:30 | 2026-05-27 | KYTX | CLARK IAN T | Dir | A - Grant | $0.00 | +5,093 | 21.7K | +31% | $0 |
| D | 2026-05-29 16:30 | 2026-05-27 | KYTX | Cohen Fred E | Dir | A - Grant | $0.00 | +5,093 | 21.7K | +31% | $0 |
| D | 2026-05-29 16:30 | 2026-05-27 | KYTX | SEIDENBERG BETH C | Dir | A - Grant | $0.00 | +5,093 | 21.7K | +31% | $0 |
| 2026-05-29 16:30 | 2026-05-27 | KYTX | Shaw Christi | Executive COB, Dir | F - Tax | $8.59 | -4,194 | 66.7K | -6% | -$36.0K | |
| D | 2026-05-29 16:30 | 2026-05-27 | KYTX | Aktar Mert | Dir | A - Grant | $0.00 | +5,093 | 21.7K | +31% | $0 |
| D | 2026-03-17 | 2026-03-13 | KYTX | Biddle Warner Weston | CEO, Dir | A - Grant | $0.00 | +58.0K | 58.0K | New | $0 |
| D | 2026-03-17 | 2026-03-13 | KYTX | GEHCHAN NAJI | See Remarks | A - Grant | $0.00 | +18.0K | 18.0K | New | $0 |
| D | 2026-03-17 | 2026-03-13 | KYTX | GRASSO MARC | CFO | A - Grant | $0.00 | +10.0K | 10.0K | New | $0 |
| D | 2026-03-04 | 2026-02-24 | KYTX | Miller Andrew Craig | Dir | A - Grant | $0.00 | +11.0K | 11.0K | New | $0 |
| D | 2026-02-26 | 2026-02-24 | KYTX | Emany Sravan Kumar | Dir | A - Grant | $0.00 | +11.0K | 11.0K | New | $0 |
| DM | 2026-01-14 | 2026-01-12 | KYTX | Shaw Christi | Executive COB, Dir | A - Grant | $0.00 | +54.3K | 70.9K | +326% | $0 |
| I | 2025-12-22 | 2025-12-18 | KYTX | SEIDENBERG BETH C | Dir | P - Purchase | $7.50 | +133.3K | 869.3K | +18% | +$1000.0K |
| I | 2025-12-22 | 2025-12-18 | KYTX | Westlake BioPartners Opportunity Fund I, L.P. | 10% | P - Purchase | $7.50 | +133.3K | 869.3K | +18% | +$1000.0K |
| DT | 2025-12-17 | 2025-12-15 | KYTX | Walker Karen Marie | CTO | M - OptEx | $4.83 | +24.0K | 46.6K | +106% | +$115.9K |
| DT | 2025-12-17 | 2025-12-15 | KYTX | Walker Karen Marie | CTO | S - Sale+OE | $12.20 | -24.0K | 22.6K | -51% | -$292.8K |
| D | 2025-06-02 | 2025-05-29 | KYTX | Aktar Mert | Dir | A - Grant | $0.00 | +16.6K | 16.6K | New | $0 |
| D | 2025-06-02 | 2025-05-29 | KYTX | Shaw Christi | Dir | A - Grant | $0.00 | +16.6K | 16.6K | New | $0 |
| D | 2025-06-02 | 2025-05-29 | KYTX | SEIDENBERG BETH C | Dir, 10% | A - Grant | $0.00 | +16.6K | 16.6K | New | $0 |
| D | 2025-06-02 | 2025-05-29 | KYTX | CLARK IAN T | Dir | A - Grant | $0.00 | +16.6K | 16.6K | New | $0 |
| D | 2025-06-02 | 2025-05-29 | KYTX | SPIEGELMAN DANIEL K | Dir | A - Grant | $0.00 | +16.6K | 16.6K | New | $0 |
| D | 2025-06-02 | 2025-05-29 | KYTX | Cohen Fred E | Dir, 10% | A - Grant | $0.00 | +16.6K | 16.6K | New | $0 |
| D | 2025-04-15 | 2025-04-11 | KYTX | Jones Ryan Alexander | CFO | A - Grant | $0.00 | +12.0K | 56.0K | +27% | $0 |
| D | 2025-04-15 | 2025-04-11 | KYTX | Walker Karen Marie | CTO | A - Grant | $0.00 | +13.0K | 22.6K | +135% | $0 |
| D | 2024-06-10 | 2024-06-06 | KYTX | Walker Karen Marie | CTO | M - OptEx | $4.42 | +9,636 | 9,636 | New | +$42.6K |
| DM | 2024-05-29 | 2024-05-28 | KYTX | Jones Ryan Alexander | CFO | M - OptEx | $0.73 | +18.0K | 44.0K | +69% | +$13.2K |
| DI | 2024-02-14 | 2024-02-12 | KYTX | Cohen Fred E | Dir, 10% | C - Cnv Deriv | — | +4.52M | 4.52M | New | — |
| DI | 2024-02-14 | 2024-02-12 | KYTX | Vida Ventures GP III, L.L.C. | 10% | C - Cnv Deriv | — | +4.52M | 4.52M | New | — |
| DMI | 2024-02-14 | 2024-02-12 | KYTX | Vida Ventures GP III, L.L.C. | 10% | P - Purchase | $22.00 | +253.1K | 583 | New | +$5.57M |
| DMI | 2024-02-14 | 2024-02-12 | KYTX | SEIDENBERG BETH C | Dir, 10% | C - Cnv Deriv | — | +4.52M | 736.0K | New | — |
| DI | 2024-02-14 | 2024-02-12 | KYTX | Bain Capital Life Sciences Fund III, L.P. | 10% | C - Cnv Deriv | — | +2.71M | 2.71M | New | — |
| DI | 2024-02-14 | 2024-02-12 | KYTX | Bain Capital Life Sciences Fund III, L.P. | 10% | P - Purchase | $22.00 | +450.0K | 3.16M | +17% | +$9.90M |
| DMI | 2024-02-14 | 2024-02-12 | KYTX | Westlake BioPartners GP I, LLC | 10% | C - Cnv Deriv | — | +4.52M | 736.0K | New | — |
| D | 2024-02-13 | 2024-02-12 | KYTX | GILEAD SCIENCES, INC. | 10% | C - Cnv Deriv | — | +3.22M | 3.22M | New | — |
| D | 2024-02-13 | 2024-02-12 | KYTX | GILEAD SCIENCES, INC. | 10% | P - Purchase | $22.00 | +910.0K | 4.13M | +28% | +$20.02M |
| DI | 2024-02-12 | 2024-02-12 | KYTX | Northpond Ventures III GP, LLC | Former 10% Owner | P - Purchase | $22.00 | +450.0K | 450.0K | New | +$9.90M |
| DI | 2024-02-12 | 2024-02-12 | KYTX | Northpond Ventures III GP, LLC | Former 10% Owner | C - Cnv Deriv | — | +2.81M | 2.81M | New | — |
Purchase Sale Sale after option exercise All abbreviations